Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.04 |
mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.04 |
mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.04 |
mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.04 |
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.081 | 0.04 |
mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.081 | 0.04 |
mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.04 |